Efficacy and Safety of Favipiravir, an Oral RNA-Dependent RNA Polymerase Inhibitor, in Mild-to-Moderate COVID-19: A Randomized, Comparative, Open-Label, Multicenter, Phase 3 Clinical Trial

Udwadia et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2020.11.142

Udwadia et al., Efficacy and Safety of Favipiravir, an Oral RNA-Dependent RNA Polymerase Inhibitor, in Mild-to-Moderate.., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2020.11.142

Nov 2020 Source PDF

Twitter
Facebook

All Studies Meta

RCT with 75 favipiravir patients and 75 control patients showing reduced time to clinical cure and reduced time of viral shedding.

Important missing comments or errors? Let us know.

recovery time, 40.0% lower, relative time 0.60, p = 0.03, treatment 75, control 75.

time to viral-, 29.0% lower, relative time 0.71, p = 0.13, treatment 75, control 75.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Udwadia et al., 16 Nov 2020, Randomized Controlled Trial, India, peer-reviewed, 11 authors.

All Studies Meta Analysis Submit Updates or Corrections

This Paper Favipiravir All

Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial

Zarir F Udwadia, Pawan Singh, Hanmant Barkate, Saiprasad Patil, Shabbir Rangwala, Amol Pendse, Jatin Kadam, Wen Wu, Cynthia F Caracta, Monika Tandon

International Journal of Infectious Diseases, doi:10.1016/j.ijid.2020.11.142

To assess the efficacy and safety of favipiravir in adults with mild-to-moderate coronavirus disease 2019 . Methods: In this randomized, open-label, parallel-arm, multicenter, phase 3 trial, adults (18-75 years) with RT-PCR confirmed COVID-19 and mild-to-moderate symptoms (including asymptomatic) were randomized 1:1 to oral favipiravir (day 1: 1800 mg BID and days 2À14: 800 mg BID) plus standard supportive care versus supportive care alone. The primary endpoint was time to the cessation of viral shedding; time to clinical cure was also measured. Results: From May 14 to July 3, 2020, 150 patients were randomized to favipiravir (n = 75) or control (n = 75). Median time to the cessation of viral shedding was 5 days (95% CI: 4 days, 7 days) versus 7 days (95% CI: 5 days, 8 days), P = 0.129, and median time to clinical cure was 3 days (95% CI: 3 days, 4 days) versus 5 days (95% CI: 4 days, 6 days), P = 0.030, for favipiravir and control, respectively. Adverse events were observed in 36% of favipiravir and 8% of control patients. One control patient died due to worsening disease. Conclusion: The lack of statistical significance on the primary endpoint was confounded by limitations of the RT-PCR assay. Significant improvement in time to clinical cure suggests favipiravir may be beneficial in mild-to-moderate COVID-19.

Conflict of interest Monika Tandon, Pawan Singh, Hanmant Barkate, Saiprasad Patil, Shabbir Rangwala, Amol Pendse, and Jatin Kadam are fulltime employees of Glenmark Pharmaceuticals Limited, India. Wen Wu is a full-time employee of Glenmark Pharmaceuticals Ltd, United Kingdom. Cynthia Caracta is a full-time employee of Glenmark Pharmaceuticals Inc., USA. Zarir F Udwadia received an investigator grant from Glenmark Pharmaceuticals Limited, India, as a site principal investigator for this study. Ethical approval The protocol and informed consent form were approved by institutional/independent ethics committees and the Drugs Controller General of India (April 26, 2020) . The trial was undertaken in accordance with current guidelines of the Central Drugs Standard Control Organization, which is the National Regulatory Authority in India, the International Conference on Harmonization Good Clinical Practice, and the Declaration of Helsinki. All patients provided written informed consent. Contributions Author contributions: All authors contributed equally to this report. Zarir F Udwadia, Monika Tandon, Pawan Singh, Hanmant Barkate, Shabbir Rangwala, Amol Pendse, and Wen Wu had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Monika Tandon, Pawan Singh, Hanmant Barkate, Saiprasad Patil, and Wen Wu. Acquisition, analysis, or interpretation of data: Jatin Kadam, Amol..

References

Agrawal, Raju, Udwadia, Favipiravir: a new and emerging antiviral option in COVID-19, Med J Armed Forces India, doi:[368_TD$DIFF]10.1016/j.mjafi.2020.08.004

Buonaguro, Tagliamonte, Tornesello, Buonaguro, SARS-CoV-2 RNA polymerase as target for antiviral therapy, J Transl Med

Cai, Yang, Liu, Experimental treatment with favipiravir for COVID-19: an open-label control study, Engineering

Carmo, Pereira-Vaz, Mota, Clearance and persistence of SARS-CoV-2 RNA in patients with COVID-19, J Med Virol

Chen, Huang, Cheng, Favipiravir versus Arbidol for COVID-19: a randomized clinical trial, MedRxiv, doi:10.1101/2020.03.17.20037432

Delang, Abdelnabi, Neyts, Favipiravir as a potential countermeasure against neglected and emerging RNA viruses, Antiviral Res

Doi, Hibino, Hase, A prospective, randomized, open-label trial of early versus late favipiravir in hospitalized patients with COVID-19, Antimicrob Agents Chemother, doi:10.1128/AAC.01897-20

Dong, Hu, Gao, Discovering drugs to treat coronavirus disease 2019 (COVID-19), Drug Discov Ther

Fu, Han, Zhu, Risk factors for viral RNA shedding in COVID-19 patients, Eur Respir J, doi:10.1183/13993003.01190-2020

Furuta, Gowen, Takahashi, Shiraki, Smee et al., Favipiravir (T-705), a novel viral RNA polymerase inhibitor, Antiviral Res

Furuta, Komeno, Nakamura, Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase, Proc Jpn Acad Ser B Phys Biol Sci

Gogtay, Ravi, Thatte, Regulatory requirements for clinical trials in India: what academicians need to know, Indian J Anaesth

Goyal, Cardozo-Ojeda Fabian, Schiffer, Potency and timing of antiviral therapy as determinants of duration of SARS CoV-2 shedding and intensity of inflammatory response, Sci Adv, doi:10.1126/sciadv.abc7112

Heneghan, Onakpoya, Jones, Neuraminidase inhibitors for influenza: a systematic review and meta-analysis of regulatory and mortality data, Health Technol Assess

Ivashchenko, Dmitriev, Vostokova, AVIFAVIR for treatment of patients with moderate COVID-19: interim results of a phase II/III multicenter randomized clinical trial, Clin Infect Dis, doi:[382_TD$DIFF]10.1093/cid/ciaa1176

Pilkington, Pepperrell, Hill, A review of the safety of favipiravir-a potential treatment in the COVID-19 pandemic?, J Virus Erad

Qi, Yang, Jiang, Factors associated with the duration of viral shedding in adults with COVID-19 outside of Wuhan, China: a retrospective cohort study, Int J Infect Dis

Sanders, Monogue, Jodlowski, Cutrell, Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review, JAMA

Schiffer, Johnston, Corey, Song, Zhang et al., COVID-19 treatment: close to a cure? A rapid review of pharmacotherapies for the novel coronavirus, Int J Antimicrob Agents

Spinner, Gottlieb, Criner, Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial, JAMA

Udwadia, Singh, Barkate, None, International Journal of Infectious Diseases

Widders, Broom, Broom, SARS-CoV-2: the viral shedding vs infectivity dilemma, Infect Dis Health

Wu, Mcgoogan, Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention, JAMA

Xu, Chen, Yuan, Factors associated with prolonged viral RNA shedding in patients with coronavirus disease 2019 (COVID-19), Clin Infect Dis

Zhou, Yang, Wang, A pneumonia outbreak associated with a new coronavirus of probable bat origin, Nature

Download Image

Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit